A weekly healthcare podcast series hosted by PwC's Health Research Institute that addresses industry trends and timely health policy topics impacting patients, providers, payers, pharmaceutical and life sciences companies as well as vendors and new entrants.
PwC's Health Research Institute
Tune in as Glenn Hunzinger, PwC's Health Industries Leader, and Phil Scalfani, PwC's Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration's executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader drug supply chain, and share perspectives on how organizations can navigate the uncertainty ahead. Discussion Highlights: The MFN executive order is a bold attempt to lower U.S. drug prices by benchmarking them against the lowest prices paid in other high-income countriesPharma companies may be forced to rethink global pricing strategies, balancing U.S. price cuts with potential increases or market exits abroadA proposed shift to direct-to-consumer drug access could disrupt traditional roles for pharmacies, distributors, and pharmacy benefit managers (PBMs)Companies are preparing for significant uncertainty by reassessing deals, modeling financial impacts, and closely monitoring upcoming rulemaking and potential legal developmentsSpeakers:Glenn Hunzinger, Health Industries Leader, PwCPhilip Sclafani, Partner, Pharma & Life Sciences, PwCLinked materials:Most Favored Nation prescription drug pricing Executive OrderFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as Glenn Hunzinger, PwC's Health Industries Leader, connects with Matt Rich, PwC's Pharma and Life Sciences R&D Leader, to unpack the recent disruption at the FDA and what it means for the pharmaceutical and biotech sectors. They discuss how companies can stay agile in the face of regulatory uncertainty, avoid preventable delays, and take practical steps to move programs forward with clarity.Discussion highlights:Ongoing restructuring at the FDA is creating uncertainty and delays in drug and device approvals, with wide-ranging impacts across the pharma, biotech and medtech landscape.While companies can't control the regulatory environment, they can focus on improving internal speed, efficiency, and submission quality to keep programs moving forwardAvoiding preventable missteps, or “foot faults,” in data, endpoints, and submission packages is critical to reducing review delays and regulatory pushbackDiversifying risk by pursuing parallel regulatory pathways in other regions such as Europe and Japan can help accelerate access and reduce dependency on a single agencyIn the absence of a clear playbook, companies should focus on what they can control by applying past lessons, staying disciplined, and collaborating across the industry to support more efficient FDA review processesSpeakers:Matt Rich, PwC's Pharmaceutical and Life Sciences R&D LeaderGlenn Hunzinger, Partner, Health Industries Leader, PwCLinked materials:Navigating the FDA disruption: 4 key actions for pharmaFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as Glenn Hunzinger, PwC's Health Industries Leader and Roel van den Akker, PwC's Pharma and Life Sciences Deals Leader discuss the rapid rise of China's biotech industry and what it means for U.S. pharmaceutical companies. They discuss the evolving role of Chinese biotech in the global innovation landscape and share perspectives on how U.S. pharmaceutical companies can thoughtfully assess opportunities, manage cross-border complexities, and build effective partnering and diligence strategies. Discussion highlights:China's biotech industry is growing fast and becoming a global player, with U.S. companies increasingly looking to partner with Chinese firms on cutting-edge scienceU.S. pharma leaders are encouraged to move beyond skepticism and stay curious by building relationships, learning from local innovation, and exploring new partnership opportunitiesSuccessfully partnering with Chinese biotech firms requires a careful and well-structured approach that accounts for global complexity, protects data and IP, and uses creative deal structures like new company formations to manage risk and stay flexibleU.S. companies need to be proactive in order to stay competitive by actively exploring global innovation, understanding the risks, and having a clear strategy to bring high-potential science to U.S. patientsSpeakers:Roel Van den Akker, Pharmaceutical and Life Sciences Deals Leader Glenn Hunzinger, Partner, Health Industries Leader, PwCLinked materials:China's rise as a biotech innovation hub: 4 key strategic questions for US biopharma executivesFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Disclaimer: This episode was recorded on April 11th, 2025, and reflects the information available at the time of recording. As we know, America is in motion here, and so subsequent updates may not be reflected in this discussion as things continue to evolve and change. Tune in as PwC specialists from across the health industry share their insights on how recent policy shifts under the Trump administration could shape healthcare in the years to come. In this episode, Glenn Hunzinger, Jenny Colapietro, and guests Kelly Griffin, Phil Sclafani, and Ruchita Kewalramani break down the potential implications of proposed government healthcare cuts, tariff policy and agency workforce reductions, along with the growing role of AI in the industry. They also discuss how pharma, medtech, payers and providers can stay ahead amidst the uncertainty. Discussion highlights:Proposed funding cuts to major government healthcare programs like Medicare, Medicaid, and NIH could significantly disrupt access, affordability, and service delivery across the healthcare landscape.Workforce reductions at federal agencies like the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and Health and Human Services (HHS) may slow drug approvals, diminish oversight, and impact public health standards.New and evolving tariff policies are creating cost pressures across pharmaceutical and medtech supply chains, with potential downstream impacts on pricing, R&D, and patient access.The rapid adoption of AI in healthcare is creating new opportunities across diagnostics, R&D, and operations, while also raising concerns around governance and data privacy.To stay ahead, industry leaders must assess risks, strengthen agility, and uncover opportunities to innovate in today's dynamic environment.Speakers:Kelly Griffin, Director, Health Policy Intelligence Institute, PwCRuchita Kewalramani, Partner, Health Services PwCPhil Sclafani, Partner, Pharma & Life Sciences, PwCGlenn Hunzinger, Partner, Health Industries Leader, PwCJenny Colapietro, Principal, Consulting Commercial Leader, PwCLinked materials:Health Policy and Intelligence InstituteFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as PwC's Pharmaceutical & Life Sciences Advisory Leader, Greg Rotz reflects on key market dynamics and explores how pharma leaders can tackle challenges including the $400 billion patent cliff, increasing competition, drug pricing pressures, and transformative disruptions shaping the industry. Discussion highlights:Understanding the scale and implications of the upcoming patent cliff and economic pressures from regulatory changes like the Inflation Reduction ActExamining heightened competition across therapeutic areas and the rapid emergence of rival treatments affecting market economicsHighlighting the necessity for bold strategic moves and critical capabilities, including AI innovation, portfolio optimization, strategic partnerships, and comprehensive risk managementAddressing disruptive forces such as geopolitical uncertainty, tariff impacts, and the rise of global innovation influencing pharmaceutical marketsEmphasizing the urgency for pharma leaders to embrace innovation and transformative strategies to improve healthcare affordability, accessibility, and qualitySpeakers:Greg Rotz, Pharmaceutical & Life Sciences Leader,PwCGlenn Hunzinger, Health Industries Leader, PwCJenny Colapietro, Consulting Commercial Leader, PwCLinked materials:Next in pharma 2025: The future is nowPharmaceutical and life sciences: US Deals 2025 outlookPresident Donald J. Trump's healthcare agendaFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as PwC specialists discuss the 2025 healthcare outlook, reflecting on 2024's significant events and exploring how payers and providers can navigate rising costs, scrutiny, AI advances, and policy shifts with resilience and adaptability. Topics include:Medicare and Medicaid drive industry growth amid rising competition, market exits, M&A, AI adoption, and policy challenges.AI's potential to enhance healthcare delivery, improve workforce management, and optimize patient care.The care-at-home market is growing rapidly, driven by demand and cost efficiency, but sustainability remains a challenge.Encouragement for healthcare organizations to adapt and innovate in response to policy shifts and technological advancements.Topics: Health services, sustainability, value-based care, insurers, pharmaceuticals, innovation, transformation, technology, business model reinvention, trust, providers, patients, economics, AI, healthcare, consumer, payers, M&A, deals, strategy, health systems, Generative AI, investments, health industries, consumerism, cyber, cyber attacks, regulatoryFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to listen as PwC's leaders Roel van den Akker and Nick Donkar provide insights into the 2024 deals landscape and offer a preview of what lies ahead. Topics include:Key topics include:A look back at M&A activity in health industries in 2024The challenges and potential impediments that could affect deal volumes in the coming yearHow artificial intelligence and tech innovations are reshaping the volume and nature of healthcare transactionsKey trends and developments to watch for with emphasis on growth, strategic assessments and regulatory factorsSpeakers:Roel van den Akker, Pharmaceutical and Life Sciences Deals Leader, PwCNick Donkar, Health Services Deals Leader, PwCJenny Colapietro, Consulting Commercial Leader, PwCLinked materials:https://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.htmlhttps://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as authors of PwC's U.S. Healthcare Climate Survey discuss key findings and provide insights into understanding healthcare organizations' responses to climate change, the integration of climate strategies, and the challenges faced in implementation.Key topics include:The survey's background, focus, and objectives that address the prioritization of climate strategies by healthcare organizations in response to climate change impactsDifferences in climate strategy approaches across sectors, reveals significant disparities in priorities and operational needs amongst payers, providers, pharmaceutical, and medtech companiesKey statistics and insights on organizational behavior and perceptions related to climate strategy integration, sustainability, and the impact on human healthConsiderations for healthcare stakeholders to enhance climate strategy implementation and address the evolving needs of diverse communities affected by climate changeSpeakers:Mackenzie Daly, Partner, PwCStacie Gitkin, Director, PwCJenny Colapietro, Consulting Commercial Leader, PwCLinked materials:https://www.pwc.com/us/en/industries/health-industries/library/impact-of-climate-change-on-human-health.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as authors of PwC's U.S. Healthcare Consumer Insights and Engagement Survey discuss key findings and provide insights into understanding consumer concerns around healthcare costs, the adoption of tech-enabled healthcare, trust in the healthcare system and how we can take action. Key topics include:The survey's background, focus and objectives that will address ongoing consumer concerns and distrust in the healthcare systemGenerational and financial differences reveal significant disparities in healthcare experiences and engagement amongst various age groups Notable key statistics and insights on consumer behavior and perceptions related to trust, affordability, delayed care and digital health across the health ecosystemConsiderations for healthcare stakeholders to enhance care delivery and to address the evolving needs of diverse patient populationsSpeakers:Thom Bales, Health Services Leader, PwCKeith Fengler, Customer Service and Channels Lead, PwC, Omar Chane, Principal, PwC. Jenny Colapietro, Consulting Commercial Leader, PwCLinked materials:https://www.pwc.com/us/en/industries/health-industries/library/healthcare-consumer-insights-survey.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
How can medtech companies drive growth in today's market? Tune in as PwC specialists return to share key insights and strategies to help medtech companies invest in the capabilities required to compete in the future while aiming to exceed near-term expectations for growth and margin improvement.Key topics include:Challenges currently faced by medtech companiesReevaluating business models and new ways to playDriving returns on historical investments in technology by leveraging data and transforming legacy processesEmbracing a “high-tech” mindset to enable change and creating a culture of empowered decision makersUnlocking value through strategic M&ASpeakers:James Woods, Principal, PwCKevin McLellan, Principal, Strategy&, PwCLuna Corbetta, Principal, PwCJenny Colapietro, Consulting Commercial Leader, PwCMaterials:https://www.pwc.com/us/en/industries/health-industries/medical-technology/medtech-industry-insights.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
What can the health industry expect from a second Trump administration? Tune in to hear what executives should watch over the next few months and years to come. Key topics include:President-elect Trump's healthcare agenda and his focus on deregulation, flexibility and choice, and accessibilityPotential implications for medicare, the ACA and IRA drug negotiationsWhat to watch in the first 100 daysSpeakers:Kelly Griffin, Director, Health Policy and Intelligence Institute Jenny Colapietro, Consulting Commercial Leader, PwCLinked materials:https://www.pwc.com/us/en/industries/health-industries/library/election-2024-trump-health-agenda.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as PwC specialists discuss best practices for securing a seat on an emerging company board. Key topics include:Types of emerging companiesResponsibilities of serving on emerging company boardsFive strategies for securing a board positionImportance of industry-specific expertise and continuous learningSpeakers:Holly Reeves, Partner, Emerging Company Solutions Market Leader, Health Industries, PwC USCarin Robinson, Director, Governance Insights Center, PwC US Jenny Colapietro, Consulting Commercial Leader, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as authors of PwC's 2025 Medical Cost Trend Report: Behind the Numbers, discuss key findings and provide what employers should consider to manage rising healthcare costs. Key points include:Cost projections: The highest medical cost trend in 13 years, with an 8% increase for the group market and 7.5% for the individual marketKey drivers: Inflation, providers' cost-control efforts, increased use of prescription drugs, and new innovative therapiesStrategic adjustments: Employers should revise benefit plans and consider innovative solutions to manage rising costs while ensuring access to quality careSpeakers:Thom Bales, Health Services Advisory Leader, PwCPhil Sclafani, Principal, Pharmaceutical and Life Sciences, PwCJulian Levin, Principal, Actuarial Leader, PwCJenny Colapietro, Consulting Commercial Leader, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as PwC specialists discuss how emerging companies (private, pre-IPO) are navigating growth in the health industry. Key topics include:The journey and milestones of emerging companies in the life sciences, biotech and medical technology fields, including capital raising, product development and IPO preparationCommon pitfalls and best practices for managing diverse interests from investors and stakeholdersExamples of how emerging companies are leveraging AI and other technologies to prioritize programs, design clinical trials and communicate value propositionSpeakers:Holly Reeves, Health Industries - Emerging Company Solutions Market Leader, PwC USChristian Jester, Technology, Media & Telecommunications - Emerging Company Solutions Market Leader, PwC USJenny Colapietro, Health Industries Vice Chair, PwC, USFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as PwC specialists discuss the 2024 outlook for healthcare and how the sector can grow and innovate amid economic challenges and uncertainty. Key Topics include:Major forces impacting the sector: economic pressure, rising costs, labor shortage, and expensive drugsWays to overcome compression and deliver value: industry-wide transformation, tech enabled business model reinvention, transactions and deals to drive transformation, and building trustSpeakers: Laura Robinette, Health Industries Trust Solutions Leader, PwC, US Thom Bales, Health Services Leader, PwC, USJenny Colapietro, Health Industries Vice Chair, PwC, USFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss strategies to reinvent the pharma business model and drive growth in the pharmaceutical industry. Key topics include:The headwinds for pharma are real and sustained Rethinking the innovation strategy Accelerate using AI and analytics Lower costs M&A as a catalyst for transformation Protecting the enterpriseSpeakers:Jenny Colapietro, Health Industries Vice Chair, PwC Glenn Hunzinger, Pharmaceutical and Life Sciences Leader, PwCGreg Rotz, Pharmaceutical and Life Sciences Advisory Leader, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC Deals leaders discuss preparing for deals in 2024, exploring the current state of the deals market and sharing valuable insights from their newly released 2024 deals outlook. Key topics include:Fundamental changes and strategy trends for 2024 and how it's shaping the health services and pharma landscapesThe role of the regulators and their impact on dealsBusiness model reinvention and the use of new technology to acquire better data and how it's shaping the deals environment for 2024What's on the horizon: Key success factors for good deal making in 2024Speakers: Roel van den Akker, Pharmaceutical and Life Sciences Deals Leader, PwCNick Donkar, Health Services Deals Leader, PwCJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss how health ecospheres can provide a transformative model for organizations to collaborate and address large-scale healthcare problems. Topics include:Identifying areas of historical shortcomingsUnderstanding strengths and capabilitiesDetermining the role within the ecosphereSpeakers:Dave Powell, Enterprise Strategy Lead Principal, PwCTyler Mansfield, Enterprise Strategy Principal, PwCJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in as health leader, author and entrepreneur, Stephen Pollak, PhD, shares how the outcomes of his research in hemodialysis populations and beyond are paving the path for data-driven solutions that inform and integrate care for patients with complex chronic conditions. Topics include:Patient medical records playing a vital role in improving medical practice outcomes and costsShifting the focus to emphasize on a results-oriented approach to inform decision-makingOvercoming sustainability and affordability challenges through clinical modelsThe role of AI in healthcareSpeakers:Stephen Pollak, PhD Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss re-engineering the healthcare ecosystem by engaging healthcare consumers. Topics include: Evaluating the consumer experience and engagementTrends in the market to help organizations develop and focus on their mission to enhance consumer experience and key investmentsThree capabilities that are needed to deliver on the promise of personalization, low cost, experience, and convenience Speakers:Derek Gaasch, Customer Transformation Principal, PwCElizabeth Carlson, Customer Transformation Director, PwCKristen Knudson, Enterprise Transformation Senior Manager, PwCIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear Barrett Baker of Project Horizon from the Sunflower Network, and Dan Solchanyk from Razom, discuss how to strengthen Ukraine's healthcare infrastructure both for the near and the long term. Topics include:Sunflower Network's mission is to deliver aid and infrastructure to communities in crisis. Project Horizon furthers this mission by building a hospital in Ukraine, empowering local healthcare workers with the infrastructure needed to deliver high quality care to their patients, and setting the stage for a larger rebuild of Ukraine's healthcare systemRazom Health: Providing critical supplies, equipment, training and preparing for long-term sustainabilityChallenges and strategies to find the right balance between speed, providing high quality enduring solutions, and mitigating risksExamples of how determination and perseverance of the Ukraine communities are pioneering innovative healthcare solutionsSpeakers:Barrett Baker, Project Lead, Sunflower NetworkDan Solchanyk, Program Director, Razom HealthIgor Belokrinitsky, Strategy& Principal, PwC Jenny Colapietro, Health Industries Vice Chair, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear Chris Barnett, Chris Barnett, CEO of ABA Centers of America, discuss his approach to a comprehensive healthcare system, with a specific emphasis on new models, technologies, and algorithms that promote inclusivity for improved behavioral health care outcomes. Topics include:The origin of Applied Behavioral Analysis (ABA) and how it seek to change lives by helping change behavior of patients on the spectrum, improving their lives and those around them. Examples of offering play-based therapies to achieve better outcomes and experiences for patients that are non-verbalChallenges and issues faced in the behavioral health space and solutions to help prevent workforce burnout and increase benefit options for staffHow ABA is using AI and technology to gain better data and insightsSpeakers:Chris Barnett, CEO, ABA Centers of America Jenny Colapietro, Health Industries Vice Chair, PwCIgor Belokrinitsky, Strategy& Principal, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss their recently published article: How a local-first strategy in China can help global pharma and life sciences players reduce risk and drive growth. Topics include:Sharing key strategies for pharma companies contemplating localization in China, offering valuable insights on maximizing business growth while mitigating risks in the Chinese marketThree approaches organizations can consider to competing at a local level in ChinaImpacts to different functions across the value chain such as R&D, supply chain, and ITSpeakers:Nalneesh Gaur, Partner, Pharmaceutical and Life Sciences Cybersecurity, PwC Ben Rhee, Principal, Pharmaceutical and Life Sciences Enterprise Strategy and Value, PwCIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
People across the world are suffering from behavioral and mental health challenges. Tune in to hear Eric Hren, Chief Growth Officer at Innowell, discuss how technology can help provide better services and solutions for patients, clinicians and employers. Topics include:Getting to know Innowell: What it does, what it offers, and the problems it solvesReaching various populations by increasing digitization to improve wellbeing and productivity, providing real-time care and reducing waitlist timeDesigning technology to be inclusive across all populations as well as accessible to various care settingsFuture growth of Innowell: Providing preventative care and solutions to unlock better outcomes for patients, clinicians, and organizationsSpeakers:Eric Hren, Chief Growth Officer, InnowellIgor Belokrinitsky, Strategy& Principal, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss the functionality and benefits of using GenAI in health care. Topics include:How GenAI is being used todayGenAI helping health insurers drive affordability of healthcareHealth organizations managing risks posed by GenAISpeakers:Inshita Wij, Strategy& Director, PwCSri Murthy, Strategy& Director, PwCIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss using GenAI in the pharma and life sciences industry. Topics include:Key considerations for new technology and deploying GenAI responsiblyKey elements to consider for monitoring regulatory activityThe future of technology, adoption and upskilling within organizationsSpeakers:Siddhartha Bhattacharya, Cloud & Digital Principal, PwCIlana Golbin Blumenfeld, Products & Technology Director, PwCIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear how the SCAN Group is expanding their Medicare Advantage plan by launching new care entities that aim to address problems of older adults. Topics include:•Addressing national-scale industry issues such as affordability and equity, and the role SCAN Group is playing•How attributes and mindset make the legal department a great fit to oversee health equity•Initiatives and data-driven solutions to help close the gap around racial disparities•What's next for the SCAN Group: New affiliations, products, and innovationSpeakers:Sachin Jain, M.D., CEO, SCAN GroupRenee Delphin-Rodriguez, Chief Legal Office and General Counsel, SCAN GroupIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss how life sciences companies are engaging better with consumers and patients and rethinking engagement, the channels utilized and how to utilize data and technology to create meaningful impact. Topics include: •What elements create a good customer experience and why it's important•Four key principles to creating a good customer experience•Restructuring roles and focus in commercial and medical organizations as well as identifying organizational growth•Utilizing data and technology along with the new evolution of Generative AISpeakers:Elizabeth Otterman, Customer Strategy and Insights Principal, PwCJacquie Newland, Services and Channels Director, PwCIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists share key findings from their medical cost trend report, discussing healthcare affordability and its implications for employers and consumers. Topics include: The Macroeconomics environment: The impact of inflationHow the workforce shortage and physician consolidation are impacting cost and patient careIncreasing cost of drugs and health therapiesEmployer perspectives on coverage and cost sharingOutlook for healthcare systems and health plans in an ever-changing and innovative environmentSpeakers:Thom Bales, Health Services Sector Leader, PwCDerek Skoog, Principal, PwCJulian Levin, Principal, PwCJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to listen as PwC's leaders Roel van den Akker and Nick Donkar provide insights into the deals landscape 2023 and offer a preview of what lies ahead. Topics include:A look back at M&A activity in health industries so far in 2023The future of deals: The role of regulators, shareholders, and private equity in the health spaceThree areas to keep an eye on: potential legislative or tax changes, stabilization of debt markets and interest rates, and strong data setsSpeakers:Roel van den Akker, Pharmaceutical and Life Sciences Deals Leader, PwCNick Donkar, Health Services Deals Leader, PwCIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear how innovations in science, technology, reimbursement, and organizational collaboration are reshaping the oncology landscape. Topics include:Emerging therapies and new business models to drive cost efficiencies Using data and predictive analytics to enhance clinical trials and patient careOptimizing organizational collaboration and partnerships to deliver value for patients, providers, manufacturers, and payersSpeakers:Ash Malik, Strategy& Principal, PwCJenny Colapietro, Health Industries Vice Chair, PwCIgor Belokrinitsky, Strategy& Principal, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear Robbie Pottharst, CEO of myPlace Health, discuss their mission for building a health care startup to integrate better care for the elderly. Topics include:What is the PACE model?How myPlace Health works with sponsors to develop comprehensive plans and services covering areas such as behavioral health, clinical pharmacy, palliative care, and technology innovations that tackle social frailty and isolationRole of a startup in solving important problems in healthcareSpeakers: Robbie Pottharst, CEO, myPlace HealthIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear how the functional role of finance can influence companies' strategies for growth in the pharmaceutical and life sciences industry. Topics include:Challenging the operating model to get Fit for Growth: Four steps to ensuring that resources are invested in the highest-value areasDigitizing the value chain and harnessing next generation technologies like generative AI to enhance both the pace and efficiency of the businessAdapting a business model and cost structure that's aligned to the new pricing realities that the industry facesSpeakers:Tatiana Simonelli, Senior Vice President of Finance, Bristol Myers SquibbGreg Rotz, Pharmaceuticals & Life Sciences Advisory Leader, PwCJenny Colapietro, Health Industries Vice Chair, PwCIgor Belokrinitsky, Strategy& Principal, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear how incorporating immersive technology in healthcare opens new frontiers; enabling patients to embark on transformative virtual health journeys to enhance their outcomes and user experience. Topics include:Examples of the use of immersive technology and future possibilities as technology advancesPatient navigation of an acute visit: A turn-by-turn tour to provide the patient with knowledge and understanding while creating a confident and comfortable environmentGetting started: How companies can leverage the power of immersive technology within their companiesSpeakers:Patrick Maher, Strategy& Principal, PwCRyan Caruso, Director of Emerging Technologies, PwCAparna Kumar, Director of Healthcare Provider Strategy, PwCLily Shay, Manager, PwCIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear what pharma stakeholders should know about the implementation of the Drug Supply Chain Security Act. Topics include:The objective of the Drug Supply Chain Security Act and timelineSteps pharma stakeholders need to take to be D.C.S.A compliant and how to prepareReadiness checklist: Four key tips to planningPerspectives on preparation from Walgreens Speakers:Pat Lupo, Vice President of Pharmacy and Specialty Trade, WalgreensNamit Mehta, Principal, Operations Transformation, PwCIgor Belokrinitsky, Strategy& Principal, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear how pharmaceutical and life sciences companies are shifting their interactions with healthcare providers to be more helpful and informative, consolidate outreach and streamline compliance using chat platforms. Topics include:Benefits of communicating with HCPs as a team through a single portal, including sales, medical sales liaisons, and access specialistsMaintaining the appropriate compliance processes to build trust and transparencyDriving better relationships between medical science liaisons and Key Opinion Leaders (KOLs)Use cases and outlook for Flex Connect, PwC's custom platformSpeakers: Katherine Buckley, Principal, Regulatory Risk and Compliance, PwCTyler Jorgensen, Principal, Customer Transformation, PwCJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC Links:Flex Connect - https://www.pwc.com/us/en/products/flex-connect.html,For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear Dr. Ari Hoffman, Chief Clinical Officer at Collective Health, discuss how they are changing the way people experience their health benefits by making it easier to understand, navigate, access, and pay for healthcare. Topics include:The process for building a workforce health benefits platform that aims to achieve better health at lower costsCustomizing benefit plans and providing a better understanding of the system for membersThe power of digital tools and data analytics to optimize engagement, participation, and behavioral changeSpeakers:Dr. Ari Hoffman, Chief Clinical Officer, Collective HealthIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear perspectives on how healthcare organizations can be more resilient and prepared for the next pandemic. Topics include:• What healthcare organizations are doing to better prepare for the next pandemic.• Key players within the ecosystem and how they need to collaborate to gain efficiencies across the value chain.• What organizations are doing to build their speed and their scale to be able to move when the time comes. Speakers:Omar Chane, Life Sciences Commercial Practice Principal, PwC May Weiser, Pharmaceutical and Life Sciences Director, PwCJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear Charles Jones, Vaccine Industry Leader at Pfizer, discuss the future of vaccines in the marketplace. Topics include: Changes seen in the marketplace and the competitive landscape Challenges of the changing schedule for preventative products such as flu immunization, COVID-19, Pneumococcal, shingle vaccines, and moreThe role of policy makers, like The Advisory Committee on Immunization Practices (ACIP) in the US and all the various participants, and the impacts they have on the value chain and the future of the ecosystemSpeakers:Charles Jones, Vaccine Industry Leader, Pfizer Amy Hunckler, Pharma and Life Sciences Managing Director, PwC May Weiser, Pharma and Life Sciences Director, PwC Igor Belokrinitsky, Strategy& Principal, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss how advanced analytics are helping health payers use new tools to forecast and improve outcomes, experience and costs. Topics include:Improving affordability, quality and experience through more timely and actionable forecastingData science and technology to make it possibleMoving to implementationSpeakers: Sachin Bajpai, Healthcare Data and Analytics Director, PwCJohn Kiley, Data Scientist Senior Manager, PwC Jenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear Cardinal Health's President of Nuclear and Precision Health Solutions, Mike Pintek, discuss the potential of nuclear medicine and theranostics advancements in precision healthcare. Topics include:How nuclear imaging is being used to provide better insights into the diagnosis of Alzheimer's disease and new treatment therapies going forwardAdvancing strategic sourcing to strengthen the supply chain by enhancing operational resiliencySupporting access to new products and advancing precision healthcare, including the focus on theranostics strategy Speakers:Mike Pintek, President of Nuclear and Precision Health Solutions, Cardinal HealthJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear TeamBuilder's David Howard and Mea Parikh discuss how healthcare organizations can leverage digital technology to improve staffing and scheduling. Topics include:The concept and evolution of Team BuilderThe transition to help organizations solve broader industry challenges related to laborHighlights of what providers find more useful and effectiveLessons learned from getting caregivers and administrators to change the way they work while building trustSpeakers:David Howard, Founder & CEO, TeamBuilderMea Parikh, Head of Operations, TeamBuilderJenny Colapietro, Health Industries Vice Chair, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss how focusing on ESG strategies can help enhance business growth, value, and harness workforce innovation. Topics include:•How organizations can prioritize their focus on ESG strategy to enhance their business goals•The role of ESG in deals across the industry•The use of technology to measure reporting and impact of ESG•Aligning ESG strategy to workforce culture and valuesSpeakers:Pete Regis, Assurance Partner, PwCBrian Henry, ESG Transformation Managing Director, PwCWayne Lombardi, ESG Health Services Digital Assurance and Technology Principal, PwCIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss how life sciences organizations can innovate better despite margin pressure and uncertainty. Topics include:•Recalibrating R&D spend to speed innovation•Aligning across the value chain (sales, R&D, supply chain) to support new innovation•Driving creativity as well as discipline to align the innovation strategy to the overall enterprise strategySpeakers:Andy Ogrins, Strategy& Director, PwCJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear Alan Weil, Editor-in-Chief at Health Affairs, discuss what drives and improves disparities in health care. Topics include: Defining social determinants of health3 building blocks to addressing inequality: Improve communities, social responses, and ROIThe role of governance: Decision-making, measuring ROI, allocating resourcesSpeakers:Alan Weil, Editor-in-Chief, Health AffairsIgor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in for a discussion with Minal Patel, founder and CEO of Abacus Insights, on the challenges and promises of cloud transformation in healthcare. Topics include:DOT connector framework: leveraging technology to bring data together for analytics and other operational purposes.Challenges from an organizational, transformational, and technology perspective.Guidance for companies interested in improving their data usage.Speakers:Minal Patel, Founder and CEO, Abacus InsightsRavi Kalakota, Managing Director, PwCJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss how PwC's digital products are helping to solve critical challenges across the health care industry. Topics include: Digital transformation outlook and trends across the industryPwC's innovative solutions and products such as, Interactions Hub, Transparency Hub, Flex Connect and moreHow digital transformation is improving quality, equity, and affordabilitySpeakers: Rachel Moore, Products & Technology Director, PwCJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to hear PwC specialists discuss how new technology and sharing frontline experiences of nurses are helping to overcome challenges across health care organizations. Topics include:Implementing digital tools, apps, hybrid delivery models, and digital preference cardsManaging labor shortages, providing more affordable care and focusing on accessibilityStrategy and results for implementing new technology tools in digital health organizationsSpeakers:Alena Taylor, Strategy& Principal, PwC Patrick Voight, Clinical Transformation Managing Director, PwCIgor Belokrinitsky, Strategy& Principal, PwC Jenny Colapietro, Health Industries Vice Chair, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to PwC's Next in Health to hear Denver Wallbrown, Exponential AI's Senior Vice President of Customer Success and Delivery, and PwC specialists discuss how new technology is helping to identify revenue leakage within the entire revenue management cycle of life sciences companies. Topics include: Three lifecycles that help determine where companies need support when identifying areas of revenue leakage Artificial Intelligence solutions used for real-time decisioning to make human-like decisions and solve revenue leakage problemsRealize the true value of AI to help solve business challenges across the value chainSpeakers:Denver Wallbrown, Senior Vice President of Customer Success and Delivery, Exponential AI Steve Foran, Pharmaceutical and Life Sciences Managing Director, PwC Igor Belokrinitsky, Strategy& Principal, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to PwC's Next in Health to hear Troy Smith, Blue Cross and Blue Shield of North Carolina's Cost of Care VP, discuss the importance of making healthcare more affordable through a variety of value-based care models. Topics include: The state of value-based care models and how they are evolving, implemented, and measured.Shifts from incentive to downside risk models and how healthcare is being delivered to diverse populations.Managing challenges and risks of these models such as creating contracts and standardizing quality.SpeakersTroy Smith, Cost of Care Vice President, Blue Cross and Blue Shield of North Carolina John Andrewes, Strategy& Principal, PwC Tori Fancher, Clinical Transformation Director, PwC Igor Belokrinitsky, Strategy& Principal, PwC For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tune in to PwC's Next in Health to hear PwC specialists discuss key topics for improving health organizations' performance and transformation in 2023. Topics include: Defining the six chronic issues in healthcare Greater affordability and the role of digital Solving systemic clinical workforce shortagesSpeakersThom Bales, Principal, Health Services Consulting Solutions Leader, PwCJenny Colapietro, Health Industries Vice Chair, PwC Igor Belokrinitsky, Strategy& Principal, PwC Click here to read the Next in health services 2023 Outlook reportFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.